Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of ...

Reports

2

Domains carrying it

2

First reported

18 September 2026

Latest report

19 September 2026

◆ Sectors

◆ Where

United States

◆ Timeline

1. 18 September 2026Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of ...ir.tevapharm.com
2. 19 September 2026Teva's TEV-749 olanzapine LAI shows 80% stabilization rate in schizophrenia trialclinicaltrialvanguard.com

◆ Connected developments

Situations Wire finds semantically close to this one. Proximity, not cause.

• Medincell Achieves Major Milestone with U.S. FDA Approval of WELTRUZA™ (olanzapine)15 reports · 14 domains · 10 October 2026
• U.S. FDA Accepts Teva's New Drug Application (NDA) and Grants Priority Review for ...2 reports · 2 domains · 20 August 2026
• Teva moves closer to a drug for celiac disease with positive Phase 2 results3 reports · 3 domains · 3 September 2026
• Definium says its LSD drug notched another Phase 3 win in anxiety disorder3 reports · 3 domains · 14 September 2026
• Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier ...2 reports · 2 domains · 1 September 2026
• Roche's Tecentriq wins 12th FDA indication, for stage III colon cancer2 reports · 2 domains · 9 October 2026

◆ Share

◆ Evidence

2 reports · 2 domains

• Teva's TEV-749 olanzapine LAI shows 80% stabilization rate in schizophrenia trialclinicaltrialvanguard.com · 19 September 2026
• Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of ...ir.tevapharm.com · 18 September 2026